150 related articles for article (PubMed ID: 29728986)
61. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
[TBL] [Abstract][Full Text] [Related]
62. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
Vahl TP; Tauchi M; Durler TS; Elfers EE; Fernandes TM; Bitner RD; Ellis KS; Woods SC; Seeley RJ; Herman JP; D'Alessio DA
Endocrinology; 2007 Oct; 148(10):4965-73. PubMed ID: 17584962
[TBL] [Abstract][Full Text] [Related]
63. Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans.
Kuo P; Wishart JM; Bellon M; Smout AJ; Holloway RH; Fraser RJ; Horowitz M; Jones KL; Rayner CK
J Clin Endocrinol Metab; 2010 Aug; 95(8):3893-900. PubMed ID: 20501683
[TBL] [Abstract][Full Text] [Related]
64. Patients With Long-QT Syndrome Caused by Impaired
Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
[TBL] [Abstract][Full Text] [Related]
65. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
[TBL] [Abstract][Full Text] [Related]
66. Effects of small intestinal glucose on glycaemia, insulinaemia and incretin hormone release are load-dependent in obese subjects.
Trahair LG; Marathe CS; Standfield S; Rayner CK; Feinle-Bisset C; Horowitz M; Jones KL
Int J Obes (Lond); 2017 Feb; 41(2):225-232. PubMed ID: 27840416
[TBL] [Abstract][Full Text] [Related]
67. Metabolic, stress, and inflammatory biomarker responses to glucose administration in Fischer-344 rats: intraperitoneal vs. oral delivery.
Pilon S; Holloway AC; Thomson EM
J Pharmacol Toxicol Methods; 2018; 90():1-6. PubMed ID: 29103948
[TBL] [Abstract][Full Text] [Related]
68. Rice protein hydrolysates stimulate GLP-1 secretion, reduce GLP-1 degradation, and lower the glycemic response in rats.
Ishikawa Y; Hira T; Inoue D; Harada Y; Hashimoto H; Fujii M; Kadowaki M; Hara H
Food Funct; 2015 Aug; 6(8):2525-34. PubMed ID: 26107658
[TBL] [Abstract][Full Text] [Related]
69. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
70. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
71. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
Roberge JN; Brubaker PL
Endocrinology; 1993 Jul; 133(1):233-40. PubMed ID: 8319572
[TBL] [Abstract][Full Text] [Related]
72. Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats.
Nakajima S; Hira T; Hara H
Br J Nutr; 2015 May; 113(9):1477-88. PubMed ID: 25827219
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of intragastric vs intraperitoneal glucose tolerance tests in the evaluation of insulin resistance in a rodent model of burn injury and glucagon-like polypeptide-1 treatment.
Watada S; Yu YM; Fischman AJ; Kurihara T; Shen CA; Tompkins RG; Fagan S
J Burn Care Res; 2014; 35(1):e66-72. PubMed ID: 23511296
[TBL] [Abstract][Full Text] [Related]
74. Propofol Improved Glucose Tolerance Associated with Increased FGF-21 and GLP-1 Production in Male Sprague-Dawley Rats.
Wu CC; Hung CJ; Wang YY; Lin SY; Chen WY; Kuan YH; Liao SL; Yang CP; Chen CJ
Molecules; 2020 Jul; 25(14):. PubMed ID: 32679813
[TBL] [Abstract][Full Text] [Related]
75. Central neuronal mechanisms of intestinal electrical stimulation: effects on duodenum distention-responsive (DD-R) neurons in the VMH of rats.
Zhang J; Zhu H; Chen JD
Neurosci Lett; 2009 Jun; 457(1):27-31. PubMed ID: 19429155
[TBL] [Abstract][Full Text] [Related]
76. A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1.
Qu W; Li Y; Hovgaard L; Li S; Dai W; Wang J; Zhang X; Zhang Q
Int J Nanomedicine; 2012; 7():4983-94. PubMed ID: 23028226
[TBL] [Abstract][Full Text] [Related]
77. Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes.
Yin J; Ji F; Gharibani P; Chen JD
Obes Surg; 2019 Sep; 29(9):2869-2877. PubMed ID: 31222497
[TBL] [Abstract][Full Text] [Related]
78. Inhibitory effects of intestinal electrical stimulation on food intake, weight loss and gastric emptying in rats.
Yin J; Zhang J; Chen JD
Am J Physiol Regul Integr Comp Physiol; 2007 Jul; 293(1):R78-82. PubMed ID: 17363682
[TBL] [Abstract][Full Text] [Related]
79. Oral administration of zein-based nanoparticles reduces glycemia and improves glucose tolerance in rats.
Reboredo C; González-Navarro CJ; Martínez-López AL; Irache JM
Int J Pharm; 2022 Nov; 628():122255. PubMed ID: 36191813
[TBL] [Abstract][Full Text] [Related]
80. Mechanisms and potential applications of intestinal electrical stimulation.
Yin J; Chen JD
Dig Dis Sci; 2010 May; 55(5):1208-20. PubMed ID: 19629689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
